
|Articles|December 13, 2013
New Drug Combo Delayed Disease Progression for Subgroup of Women With Metastatic Breast Cancer
Author(s)Dev Paul, DO, PhD
Advertisement
Adding dasatinib to standard antihormone therapy letrozole significantly improved the progression-free survival of women with hormone receptor–positive, HER2-negative metastatic breast cancer, according to the results of a small phase II study. Investigator Dev Paul, DO, PhD, of Rocky Mountain Cancer Centers cautioned that more information is needed to determine which patients will benefit from the addition of dasatinib.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Relacorilant Combo in Platinum-Resistant Ovarian Cancers
2
Navigating New Horizons in Neuroendocrine Prostate Cancer
3
FDA Clears Investigator-Initiated IND for SRN-101 in Recurrent High-Grade Glioma
4
The Intersection of Technology and Psycho-Oncology Care
5























































